Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) shares are down during early trading on Friday following the company’s recent financial update, which revealed a net loss for the fourth quarter.

The company reported a net loss of 73 cents per diluted share, for the fourth quarter of 2025, beating the Street view of $1.65 loss.

Acurx ended the quarter with cash totaling $7.6 million, an increase from $3.7 million a year earlier, and raised approximately $1.5 million through its Equity Line of Credit during the fourth quarter.

The company is focused on developing a new class of antibiotics, with its lead candidate, Ibezapolstat, preparing for international Phase 3 clinical trials to treat C. difficile infection.

About The Company

Acurx Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing a new class of antibiotics for infections caused by bacteria listed as priority pathogens by the World Health Organization, Centers for Disease Control and Prevention and Food and Drug Administration.

The company’s approach is to develop antibiotic candidates with a Gram-positive selective spectrum, focusing on addressing difficult-to-treat bacterial infections.

This focus is particularly relevant as antibiotic resistance continues to rise globally, making the development of new therapies crucial.

Earnings & Analyst Outlook

Acurx Pharmaceuticals, Inc. Common Stock is slated to provide its next financial update on May 12, 2026 (estimated).

• EPS Estimate: -$1.24 (Up from -$2.20)

ACXP Price Action: Acurx Pharmaceuticals shares were down 19.16% at $4.24 at the time of publication on Friday, according to Benzinga Pro data.

Photo: jittawit21/Shutterstock